<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056380</url>
  </required_header>
  <id_info>
    <org_study_id>RM01-2027</org_study_id>
    <nct_id>NCT01056380</nct_id>
  </id_info>
  <brief_title>Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romark Laboratories L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Romark Laboratories L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial designed to evaluate oral nitazoxanide compared to a
      placebo in the treatment of acute uncomplicated influenza in adults. We hypothesize that
      treatment with nitazoxanide will reduce the duration of symptoms in patients with confirmed
      influenza infection. Secondarily, we hypothesize that treatment with nitazoxanide will reduce
      the complications of influenza, severity of symptoms, time lost from work, time to return to
      normal daily activities, and viral shedding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is conducted at approximately 25 sites in the United States. Subjects selected
      based on symptoms will be randomized to receive oral nitazoxanide or placebo twice daily for
      5 days. Subjects will be monitored by daily by telephone or home visit to monitor symptoms
      and complications of influenza for safety and will be referred for medical care as required.
      Subjects will complete a diary twice daily to record the presence and severity of symptoms,
      ability to perform normal daily activities and time lost from work. Complications of
      influenza (including sinusitis, otitis, bronchitis, pneumonia, central nervous system
      disease) and other adverse events will be reported. Nasopharyngeal swabs will be collected at
      Baseline (Day 0) and Day 7 for all patients and on Days 1 through 4 for a subset of patients
      to test for influenza A (including novel H1N1), influenza B and 17 other respiratory viruses
      by RT-PCR and culture and to evaluate quantitative viral shedding. The primary analysis will
      be for patients with confirmed influenza, and secondary analyses will be conducted for
      subjects with any respiratory virus and for all treated subjects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment during 2009-2010 flu season, new study initiated.
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Resolution of All Clinical Symptoms of Influenza (Subjects With Confirmed Influenza Infection)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of All Clinical Symptoms of Influenza (Subjects Infected With Any Respiratory Virus)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of All Clinical Symptoms of Influenza (All Treated Subjects)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Normal Daily Activity (Subjects With Confirmed Influenza)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Severity of Disease Score</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Subjects recorded a severity score for 10 flu symptoms on a 0-3 scale BID for 7-14 days.The severity score for each symptom was multiplied by the number of hours scored at that severity for the entire time the subject maintained a diary (a sneezing score of 1 for 12 hours and 0 for 10 hours =1*12 + 0*10=12). This is symptom severity score*hours.Symptom severity score*hours for each of the symptoms were added for an overall symptom severity score*hours (if symptom severity score*hours for 10 symptoms were 12, 10, 9, 8, 7, 10, 10, 10, 5, 5, overall symptom severity score*hours=86).Overall symptom severity score*hours were divided by the number of hours that the subject kept a diary for a standardized continuous measure of severity of the course of illness (if overall symptom severity score*hours=86 and the subject maintained a diary for 100 hours Overall Severity of Disease Score=0.86). Overall Severity of Disease Score can range 0-30 with higher scores indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Lost From Work (Subjects With Confirmed Influenza)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of Influenza Including Secondary Illnesses, Antibiotic Use and Hospitalizations (Subjects With Confirmed Influenza)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Viral Shedding (Subjects With Confirmed Influenza)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Influenza Virus Titer Assessed by Quantitative RT-PCR (Subjects With Confirmed Influenza)</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Tablet, 500 mg with food twice daily for 5 days</description>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <other_name>Alinia, NTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, twice daily with food for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years

          -  Fever, respiratory symptoms and constitutional symptoms compatible with influenza
             infection

          -  Influenza A or B infection in the local community

          -  Onset of illness no more than 48 hours before presentation

          -  Willing and able to provide comply with protocol requirements

        Exclusion Criteria:

          -  Severity of illness requiring or anticipated to require in-hospital care

          -  High risk of complications from influenza per IDSA (Infectious Diseases Society of
             America) guidelines or current CDC (Centers for Disease Control) criteria

          -  Females pregnant, breast-feeding or sexually active without birth control

          -  Vaccination for seasonal influenza or H1N1 on or after August 1, 2009

          -  Treatment with antiviral medication for influenza within 1 month prior to screening

          -  Treatment with nitazoxanide or any investigational drug within 1 month prior to
             screening

          -  Known sensitivity to nitazoxanide or any excipients

          -  Unable to take oral medications

          -  Chronic kidney or liver disease or known impaired hepatic and/or renal function

          -  Other pre-existing chronic infection undergoing or requiring medical therapy

          -  Pre-existing illness placing subject at unreasonably increased risk by participation
             in study

          -  Unlikely to comply with the requirements of this protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Fran√ßois Rossignol, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Romark Institute for Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Sciences Research Center at Asthma and Allergy Associates, P.C.</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <results_first_submitted>November 18, 2013</results_first_submitted>
  <results_first_submitted_qc>July 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2017</results_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>influenza like illness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled at 11 primary care health centers throughout the United States in the last months of the 2009/2010 flu season</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nitazoxanide</title>
          <description>Nitazoxanide : Tablet, 500 mg with food twice daily for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo : Tablet, twice daily with food for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nitazoxanide</title>
          <description>Nitazoxanide : Tablet, 500 mg with food twice daily for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo : Tablet, twice daily with food for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="14.4"/>
                    <measurement group_id="B2" value="37.9" spread="13.3"/>
                    <measurement group_id="B3" value="38.2" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Resolution of All Clinical Symptoms of Influenza (Subjects With Confirmed Influenza Infection)</title>
        <time_frame>Up to 28 days</time_frame>
        <population>All subjects with laboratory confirmed influenza who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>Nitazoxanide : Tablet, 500 mg with food twice daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Tablet, twice daily with food for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of All Clinical Symptoms of Influenza (Subjects With Confirmed Influenza Infection)</title>
          <population>All subjects with laboratory confirmed influenza who took at least one dose of study medication.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="12" upper_limit="176"/>
                    <measurement group_id="O2" value="91.5" lower_limit="70" upper_limit="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of All Clinical Symptoms of Influenza (Subjects Infected With Any Respiratory Virus)</title>
        <time_frame>Up to 28 days</time_frame>
        <population>All subjects with any laboratory confirmed viral infection who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>Nitazoxanide: Tablet, 500 mg with food twice daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Tablet, twice daily with food for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of All Clinical Symptoms of Influenza (Subjects Infected With Any Respiratory Virus)</title>
          <population>All subjects with any laboratory confirmed viral infection who took at least one dose of study medication.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.0" lower_limit="80" upper_limit="157"/>
                    <measurement group_id="O2" value="88.8" lower_limit="70" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of All Clinical Symptoms of Influenza (All Treated Subjects)</title>
        <time_frame>Up to 28 days</time_frame>
        <population>All subjects who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>Nitazoxanide: Tablet, 500 mg with food twice daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Tablet, twice daily with food for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of All Clinical Symptoms of Influenza (All Treated Subjects)</title>
          <population>All subjects who received at least one dose of study medication.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.8" lower_limit="72" upper_limit="169"/>
                    <measurement group_id="O2" value="102.6" lower_limit="69" upper_limit="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Normal Daily Activity (Subjects With Confirmed Influenza)</title>
        <time_frame>Up to 28 days</time_frame>
        <population>All subjects with laboratory confirmed influenza who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>Nitazoxanide: Tablet, 500 mg with food twice daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Tablet, twice daily with food for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Normal Daily Activity (Subjects With Confirmed Influenza)</title>
          <population>All subjects with laboratory confirmed influenza who received at least one dose of study medication.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" lower_limit="31" upper_limit="176"/>
                    <measurement group_id="O2" value="57.5" lower_limit="21" upper_limit="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Severity of Disease Score</title>
        <description>Subjects recorded a severity score for 10 flu symptoms on a 0-3 scale BID for 7-14 days.The severity score for each symptom was multiplied by the number of hours scored at that severity for the entire time the subject maintained a diary (a sneezing score of 1 for 12 hours and 0 for 10 hours =1*12 + 0*10=12). This is symptom severity score*hours.Symptom severity score*hours for each of the symptoms were added for an overall symptom severity score*hours (if symptom severity score*hours for 10 symptoms were 12, 10, 9, 8, 7, 10, 10, 10, 5, 5, overall symptom severity score*hours=86).Overall symptom severity score*hours were divided by the number of hours that the subject kept a diary for a standardized continuous measure of severity of the course of illness (if overall symptom severity score*hours=86 and the subject maintained a diary for 100 hours Overall Severity of Disease Score=0.86). Overall Severity of Disease Score can range 0-30 with higher scores indicating more severe symptoms.</description>
        <time_frame>Up to 14 days</time_frame>
        <population>All subjects with laboratory confirmed influenza who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>Nitazoxanide: Tablet, 500 mg with food twice daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Tablet, twice daily with food for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Severity of Disease Score</title>
          <description>Subjects recorded a severity score for 10 flu symptoms on a 0-3 scale BID for 7-14 days.The severity score for each symptom was multiplied by the number of hours scored at that severity for the entire time the subject maintained a diary (a sneezing score of 1 for 12 hours and 0 for 10 hours =1*12 + 0*10=12). This is symptom severity score*hours.Symptom severity score*hours for each of the symptoms were added for an overall symptom severity score*hours (if symptom severity score*hours for 10 symptoms were 12, 10, 9, 8, 7, 10, 10, 10, 5, 5, overall symptom severity score*hours=86).Overall symptom severity score*hours were divided by the number of hours that the subject kept a diary for a standardized continuous measure of severity of the course of illness (if overall symptom severity score*hours=86 and the subject maintained a diary for 100 hours Overall Severity of Disease Score=0.86). Overall Severity of Disease Score can range 0-30 with higher scores indicating more severe symptoms.</description>
          <population>All subjects with laboratory confirmed influenza who received at least one dose of study medication.</population>
          <units>overall severity score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="3.3"/>
                    <measurement group_id="O2" value="6.2" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Lost From Work (Subjects With Confirmed Influenza)</title>
        <time_frame>Up to 28 days</time_frame>
        <population>All subjects with laboratory confirmed influenza who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>Nitazoxanide: Tablet, 500 mg with food twice daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Tablet, twice daily with food for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time Lost From Work (Subjects With Confirmed Influenza)</title>
          <population>All subjects with laboratory confirmed influenza who received at least one dose of study medication.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" lower_limit="-0.04" upper_limit="7.32"/>
                    <measurement group_id="O2" value="4.36" lower_limit="-0.70" upper_limit="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications of Influenza Including Secondary Illnesses, Antibiotic Use and Hospitalizations (Subjects With Confirmed Influenza)</title>
        <time_frame>Up to 28 days</time_frame>
        <population>All subjects with laboratory confirmed influenza who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>Nitazoxanide: Tablet, 500 mg with food twice daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Tablet, twice daily with food for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Complications of Influenza Including Secondary Illnesses, Antibiotic Use and Hospitalizations (Subjects With Confirmed Influenza)</title>
          <population>All subjects with laboratory confirmed influenza who received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of Viral Shedding (Subjects With Confirmed Influenza)</title>
        <time_frame>28 days</time_frame>
        <population>All subjects with laboratory confirmed influenza enrolled in the intensive virologic follow up substudy who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>Nitazoxanide: Tablet, 500 mg with food twice daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Tablet, twice daily with food for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of Viral Shedding (Subjects With Confirmed Influenza)</title>
          <population>All subjects with laboratory confirmed influenza enrolled in the intensive virologic follow up substudy who received at least one dose of study medication.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="95.5" upper_limit="95.5"/>
                    <measurement group_id="O2" value="83.3" lower_limit="72" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Influenza Virus Titer Assessed by Quantitative RT-PCR (Subjects With Confirmed Influenza)</title>
        <time_frame>4 days</time_frame>
        <population>All subjects with laboratory confirmed influenza enrolled in the intensive virologic follow up substudy who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>Nitazoxanide: Tablet, 500 mg with food twice daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Tablet, twice daily with food for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Influenza Virus Titer Assessed by Quantitative RT-PCR (Subjects With Confirmed Influenza)</title>
          <population>All subjects with laboratory confirmed influenza enrolled in the intensive virologic follow up substudy who received at least one dose of study medication.</population>
          <units>Quantitative PCR RNA Copies</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="-175183057" spread="373069697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="-176973304" spread="374681622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="-176946354" spread="375523235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nitazoxanide</title>
          <description>Nitazoxanide : Tablet, 500 mg with food twice daily for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo : Tablet, twice daily with food for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>Ear infection, Sinusitis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Abdominal distension, Abdominal pain upper, Diarrhea, Dysgeusia, Nausea, Oropharyngeal pain</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>Malaise, Pyrexia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscoloskeletal and connective tissue disorders</sub_title>
                <description>Arthralgia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <description>Chromaturia, Pollakiuria</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <description>Epididymitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Cough, Dyspnoea, Productive cough</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Presentation and/or publication is encouraged provided the Sponsor is notified in advance and given the opportunity to review the manuscript or abstract 30 days prior to its submission for presentation at a scientific meeting or for publication in a scientific journal. The investigators will have complete autonomy regarding the content and wording including the decision of whether or not to publish.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Marc Ayers</name_or_title>
      <organization>Romark Laboratories, L.C.</organization>
      <phone>813-282-8544</phone>
      <email>Marc.Ayers@romark.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

